CXCR家族蛋白在不同乳腺癌亚型中的表达及临床预后分析

doi:10.11904/j.issn.1002-3070.2019.03.003

实用肿瘤学杂志 ›› 2019, Vol. 33 ›› Issue (3): 206-210.doi: 10.11904/j.issn.1002-3070.2019.03.003

CXCR家族蛋白在不同乳腺癌亚型中的表达及临床预后分析

王晓雅,肖斌,廖扬,唐荣芝,孙朝晖,李林海

广州军区广州总医院检验科(广州 510010)

收稿日期:2018-10-16 修回日期:2019-02-26 出版日期:2019-06-20 发布日期:2019-06-18
通讯作者: 李林海,E-mail:mature303@126.com
作者简介:王晓雅,女,(1993-),本科,技师,从事临床生化检验的研究
基金资助:
2017年度军队后勤科研项目(编号:CWH17C017);2018年度广州市科技计划项目(编号:201804010186)

Expression of CXCR family proteins in different subtypes of breast cancer and their clinical prognosis

WANG Xiaoya,XIAO Bin,LIAO Yang,TANG Rongzhi,SUN Zhaohui,LI Linhai

Department of Laboratory Medicine,General Hospital of Guangzhou Military Command of PLA,Guangzhou 510010,China

Received:2018-10-16 Revised:2019-02-26 Online:2019-06-20 Published:2019-06-18

摘要/Abstract

摘要： 目的研究CXCR家族蛋白在乳腺癌各亚型及癌旁组织中的表达及其与患者预后的关系,为乳腺癌的临床诊断、治疗及预后提供参考依据。方法获取TCGA(The Cancer Genome Atlas)数据库中的CXCR家族蛋白在癌旁组织以及不同亚型乳腺癌组织中的mRNA表达数据;利用PRECOG网站获取各差异表达蛋白的预后生存分析图。结果除CXCR1外,各CXCR家族蛋白在乳腺癌组织与癌旁组织中表达均有统计学差异(P＜0.05);CXCR2P1、CXCR3、CXCR4、CXCR5和CXCR6在乳腺癌组织中高表达,CXCR2和CXCR7在乳腺癌组织中低表达;CXCR3、CXCR4和CXCR7的表达水平与患者的预后有关。结论 CXCR3、CXCR4和CXCR7在乳腺癌组织和癌旁组织中的表达有统计学差异,且其表达与乳腺癌患者预后相关,可能是乳腺癌分子诊断或靶向治疗的潜在靶标。

关键词: CXCR家族蛋白, 乳腺癌, TCGA, 预后

Abstract: Objective The aims of this study were to determine the expression of CXCR family proteins in various subtypes and adjacent tissues of breast cancer and its relationship with prognosis,and to provide a reference for clinical diagnosis,treatment and prognosis of breast cancer.Methods The mRNA expressive profiles of CXCR family proteins in paracancerous tissues and different subtypes of breast cancer tissues were obtained from the TCGA(The Cancer Genome Atlas)database.The prognostic survival analysis of each differentially expressed protein was obtained using the PRECOG website.Results Except for CXCR1,the expression of CXCR family proteins in breast cancer tissues and adjacent tissues was statistically different(P＜0.05).CXCR2P1,CXCR3,CXCR4,CXCR5 and CXCR6 were highly expressed in breast cancer tissues,CXCR2 and CXCR7 were lowly expressed in breast cancer tissues.The expressive levels of CXCR3,CXCR4 and CXCR7 were associated with the prognosis of patients.Conclusion The expressions of CXCR3,CXCR4 and CXCR7 in breast cancer tissues and adjacent tissues is significantly different,and its expression is related to the prognosis of breast cancer patients,which may be a potential target for molecular diagnosis or targeted therapy of breast cancer.

Key words: CXCR family proteins, Breast cancer, TCGA, Prognosis

中图分类号:

R737.9
R34

王晓雅,肖斌,廖扬,唐荣芝,孙朝晖,李林海. CXCR家族蛋白在不同乳腺癌亚型中的表达及临床预后分析[J]. 实用肿瘤学杂志, 2019, 33(3): 206-210.

WANG Xiaoya,XIAO Bin,LIAO Yang,TANG Rongzhi,SUN Zhaohui,LI Linhai. Expression of CXCR family proteins in different subtypes of breast cancer and their clinical prognosis[J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 206-210.

参考文献 1

Fan L,Strasser-weippl K,Li JJ,et al.Breast cancer in China[J].Lancet Oncol,2014,15(7):279-289.2 李林,李志高.二甲双胍与不同分子亚型乳腺癌的关系[J].实用肿瘤学杂志,2018,32(3):267-270.3 Pan XB,Chen RJ,Huang ST,et al.Systematic review and meta-analysis of the efficacy of breast conservation therapy followed by radiotherapy in four breast cancer subtypes[J].Oncotarget,2017,8(34):57414-57420.4 Battisti N,Okonji D,Manickavasagar T,et al.Outcomes of systemic therapy for advanced triple-negative breast cancer:A single centre experience[J].Breast,2018,40:60-66.5 郑正荣,杨春康,戴起宝.趋化因子受体对肿瘤生物学行为的影响[J].世界华人消化杂志,2006,14(5):513-518.6 韩堃,黎燕,陈国江.趋化因子及其受体在肿瘤转移中作用的研究进展[J].国际药学研究杂志,2012,39(5):386-390.7 Han X.Constitutively active chemokine CXC receptors[J].Adv Pharmacol,2014,70:265-301.8 Keane MP,Belperio JA,Xue YY,et al.Depletion of CXCR2 inhibits tumor growth and angiogenesis in a murine model of lung cancer[J].J Immunol,2004,172(5):2853-2860.9 Zeng Y,Wang X,Yin B,et al.Role of the stromal cell derived factor-1/CXC chemokine receptor 4 axis in the invasion and metastasis of lung cancer and mechanism[J].J Thorac Dis,2017,9(12):4947-4959.10 Choi YJ,Chang WJ,Shin SW,et al.The prognostic role of serum C-X-C chemokine receptor type 4 in patients with metastatic or recurrent colorectal cancer[J].Onco Targets Ther,2016,9:3307-3312.11 Guo ZJ,Yang L,Qian F,et al.Transcription factor RUNX2 up-regulates chemokine receptor CXCR4 to promote invasive and metastatic potentials of human gastric cancer[J].Oncotarget,2016,7(15):20999-21012.12 Yates TJ,Knapp J,Gosalbez M,et al.C-X-C chemokine receptor 7:a functionally associated molecular marker for bladder cancer[J].Cancer,2013,119(1):61-71.13 Richardsen E,Ness N,Melbo-jorgensen C,et al.The prognostic significance of CXCL16 and its receptor C-X-C chemokine receptor 6 in prostate cancer[J].Am J Pathol,2015,185(10):2722-2730.14 Miller LD,Smeds J,George J,et al.An expression signature for p53 status in human breast cancer predicts mutation status,transcriptional effects,and patient survival[J].Proc Natl Acad Sci U S A,2005,102(38):13550-13555.15 Ding Q,Xia Y,Ding S,et al.An alternatively spliced variant of CXCR3 mediates the metastasis of CD133+ liver cancer cells induced by CXCL9[J].Oncotarget,2016,7(12):14405-14444.16 Li L,Chen J,Lu ZH,et al.Significance of chemokine receptor CXCR3 expression in breast cancer[J].Zhonghua Bing Li Xue Za Zhi,2011,40(2):85-88.17 Bronger H,Karge A,Dreyer T,et al.Induction of cathepsin B by the CXCR3 chemokines CXCL9 and CXCL10 in human breast cancer cells[J].Oncol Lett,2017,13(6):4224-4230.18 Huang MB,Giesler KE,Katzman BM,et al.Small molecule CXCR4 antagonists block the HIV-1 Nef/CXCR4 axis and selectively initiate the apoptotic program in breast cancer cells[J].Oncotarget,2018,9(24):16996-17013.19 Tulotta C,Stefanescu C,Beletkaia E,et al.Inhibition of signaling between human CXCR4 and zebrafish ligands by the small molecule IT1t impairs the formation of triple-negative breast cancer early metastases in a zebrafish xenograft model[J].Dis Model Mech,2016,9(2):141-153.20 Xiao G,Wang X,Wang J,et al.CXCL16/CXCR6 chemokine signaling mediates breast cancer progression by pERK1/2-dependent mechanisms[J].Oncotarget,2015,6(16):14165-14178.21 Cheng H,Chen NY.Expression of Chemokine receptor CXCR6 and its significance in breast cancer cell lines[J].Sichuan Da Xue Xue Bao Yi Xue Ban,2014,45(3):405-409.

[1]	李烁,张楠楠,李亮亮,龙志平,尹慧慧,赵亚双,王帆. 外周血白细胞PDE4C基因甲基化及环境因素交互作用与乳腺癌发病的关系[J]. 实用肿瘤学杂志, 2019, 33(3): 233-238.
[2]	李嘉琪,栾瑾微,张,玉,李香兰. 763例三阴性乳腺癌临床病理特征及复发、转移影响因素分析[J]. 实用肿瘤学杂志, 2019, 33(3): 244-249.
[3]	冯越,邢丽楠,王棹,张云艳. NLR与肿瘤同步放化疗预后的相关性研究[J]. 实用肿瘤学杂志, 2019, 33(3): 284-288.
[4]	陈艳波, 孔德嘉, 张金锋, 马志刚. 乳腺癌患者CYP2D6基因多态性与他莫昔芬代谢相关性研究[J]. 实用肿瘤学杂志, 2019, 33(2): 110-114.
[5]	白晓斌, 霍龙伟, 谢万福, 徐高峰, 王茂德. Chk1在胶质母细胞瘤中的表达及其与肿瘤生物学行为和预后生存的关联性[J]. 实用肿瘤学杂志, 2019, 33(2): 122-127.
[6]	石小康, 丁佑铭, 汪斌, 余斌, 徐雨. UBE2T在原发性肝癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(2): 128-133.
[7]	孙江宏, 郝明珠, 姜丹, 国飞, 李晓梅. 乳腺炎、良性增生及乳腺癌FFDM鉴别诊断思路[J]. 实用肿瘤学杂志, 2019, 33(2): 139-141.
[8]	马志杰, 王帆, 赵亚双. 乳腺癌化疗患者生存质量及影响因素分析[J]. 实用肿瘤学杂志, 2019, 33(2): 149-154.
[9]	卢姣云, 张清媛. 实验室标志物在弥漫大B细胞淋巴瘤预后中的研究进展[J]. 实用肿瘤学杂志, 2019, 33(2): 183-187.
[10]	赵凤娟, 王琪, 任贇虹, 韦珏伶, 黎乐群, 赵新华, 唐娟, 游雪梅. 肝癌伴抑郁患者血清CRP、hs-CRP水平变化及其对预后的影响[J]. 实用肿瘤学杂志, 2019, 33(1): 27-33.
[11]	张凤春, 江莺, 刘照南, 闫宁宁, 崔洪全, 徐迎春. 系统性炎症相关指标中性粒细胞/淋巴细胞比值及血小板/淋巴细胞比值在根治性切除术后的胃癌患者的预后意义[J]. 实用肿瘤学杂志, 2019, 33(1): 34-39.
[12]	马健力, 张明辉, 姬宏飞, 徐向英. PD-L1蛋白与CD8⁺TILs联合检测在可切除肺腺癌预后评估中的临床意义[J]. 实用肿瘤学杂志, 2019, 33(1): 40-46.
[13]	马质莹, 尚乃舰, 蔡妙田, 沈阳, 姜智允. 孕激素及雌激素受体阳性乳腺癌HER-2受体与钼靶影像学特征及临床病理学特征的相关性分析[J]. 实用肿瘤学杂志, 2019, 33(1): 47-51.
[14]	杨洪波, 石洁, 叶勇, 李文成, 邓兆平. COL5A2在膀胱癌组织中的表达及其与临床病理特征和预后的相关性分析[J]. 实用肿瘤学杂志, 2019, 33(1): 52-56.
[15]	王亚龙, 吕章艳, 张帆, 冯小双, 魏锣沛, 李鑫, 温艳, 高禹舜, 薛奇, 高树庚, 谭锋维. 人乳头状瘤病毒感染与肺癌预后相关性的Meta分析[J]. 实用肿瘤学杂志, 2018, 32(6): 520-526.

CXCR家族蛋白在不同乳腺癌亚型中的表达及临床预后分析

Expression of CXCR family proteins in different subtypes of breast cancer and their clinical prognosis

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 1

相关文章 15

编辑推荐

Metrics

本文评价